Clinical Trials on Locally Advanced or Metastatic Cancers

Total 9858 results

Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effect of MK-8669 (Ridaforolimus) on QTc Interval in Participants With Advanced Cancer (MK-8669-037)

Metastatic or Locally Advanced Cancer
Amunix, a Sanofi Company
Merck Sharp & Dohme LLC

Recruiting

To Access the Safety and Effects of Intravenous Administration of AMX-818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

Locally Advanced or Metastatic HER2-Expressing Cancers

Australia, Spain, France, Portugal
University of Cincinnati

Not yet recruiting

Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors

Cancer | Metastatic Cancer | Locally Advanced Solid Tumor | Locally Advanced | Locally Advanced Carcinoma

United States
Gilead Sciences
Everest Medicines

Active, not recruiting

Study of Sacituzumab Govitecan-hziy (IMMU-132) Versus Treatment of Physician's Choice in Participants With Metastatic or Locally Advanced Unresectable Urothelial Cancer (TROPiCS-04)

Locally Advanced or Metastatic Unresectable Urothelial Cancer

United States, Belgium, France, Spain, United Kingdom, Korea, Republic of, Czechia, Germany, Israel, China, Italy, Australia, Hong Kong, Taiwan, Portugal, Singapore, Croatia, Greece, Turkey, Sweden, Switzerland, Canada, Austria, Bulgaria and more
Memorial Sloan Kettering Cancer Center

Completed

Use of a Video Decision Tool to Improve Informed Decision-Making in Hospitalized Patients Considering Palliative Radiation Therapy

Metastatic Cancer or Locally Advanced | Patients Receiving Palliative Radiation

United States
Letolab

Not yet recruiting

Phase II Clinical Study of LTC004 in Patients With mCRC

Locally Advanced or Metastatic CRC
Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Completed

Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy Subjects

Locally Advanced or Metastatic NSCLC

China
Takeda
Takeda Development Center Americas, Inc.

Recruiting

First-in-Human Study of TAK-280 in Participants With Unresectable Locally Advanced or Metastatic Cancer

Unresectable Locally Advanced or Metastatic Cancer

Spain, United States, Australia, Canada
Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Completed

Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole

Locally Advanced or Metastatic NSCLC

China
ImmunoGen, Inc.

Withdrawn

huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas

Stomach Neoplasms | Metastatic or Locally Advanced Gastric Cancer | Metastatic or Local Advanced GE Junction Cancer

United States
Hospices Civils de Lyon

Unknown

EVESOR: a Phase 1 Trial of Everolimus and Sorafenib (EVESOR)

Metastatic or Locally Advanced Solid Tumors

France
German Cancer Research Center

Recruiting

CRAFT: The NCT-PMO-1602 Phase II Trial

Metastatic or Locally Advanced Malignancies

Germany
University Medical Center Groningen

Active, not recruiting

MPDL3280A-treatment-IST-UMCG

Locally Advanced or Metastatic Solid Tumors

Netherlands
Merck KGaA, Darmstadt, Germany

Completed

Oral Bioavailability and Mass Balance Trial With Pimasertib

Locally Advanced or Metastatic Solid Tumors

Hungary
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors

China
Avistone Biotechnology Co., Ltd.
Zhejiang Cancer Hospital; Henan Cancer Hospital; Hunan Cancer Hospital; Peking... and other collaborators

Recruiting

A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors

China
TYK Medicines, Inc

Recruiting

A Study of TYK-00540 in Adult Patients With Solid Tumors (ASOTIAPWST)

Locally Advanced or Metastatic Solid Tumors

China
Bio-Thera Solutions

Recruiting

Assessment of Safety and Preliminary Clinical Efficacy With BAT6005 in Advanced Malignant Solid Tumors

Locally Advanced or Metastatic Solid Tumors

China
Chugai Pharmaceutical

Recruiting

A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).

Locally Advanced or Metastatic Solid Tumors

United States, Japan
Chugai Pharmaceutical

Recruiting

A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).

Locally Advanced or Metastatic Solid Tumors

United States, Japan
Pierre Fabre Medicament

Terminated

First-In-Human (FIH) Study of W0180 as Single Agent and in Combination With Pembrolizumab in Adults With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors

France, Spain
OncoMed Pharmaceuticals, Inc.
Celgene Corporation

Completed

A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors

United States, United Kingdom
Dong-A ST Co., Ltd.

Not yet recruiting

Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors
Pyrotech Therapeutics, Inc.

Recruiting

PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors

United States
Beijing StarMab Biomed Technology Ltd

Recruiting

Clinical Study of SM3321 With Solid Tumors

Locally Advanced or Metastatic Solid Tumors

China
Biocity Biopharmaceutics Co., Ltd.

Recruiting

Study of BC3195 Monotherapy in Patients With Advanced Solid Tumors (BC3195)

Locally Advanced or Metastatic Solid Tumors

China
Chinese PLA General Hospital
Wuxi Sinotide New Drug Discovery Institutes

Recruiting

IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors

China
Antengene Therapeutics Limited
Merck Sharp & Dohme LLC

Recruiting

A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors

Locally Advanced or Metastatic Solid Tumors

Australia, China
Shanghai East Hospital
Imbioray (Hangzhou) Biomedicine Co., Ltd.

Recruiting

Study of Anti-5T4 CAR-raNK Cell Therapy in Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors

China
InxMed (Shanghai) Co., Ltd.

Active, not recruiting

IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients

Locally Advanced or Metastatic Solid Tumors

China
Amphivena Therapeutics, Inc.

Active, not recruiting

Study of AMV564 in Subjects With Advanced Solid Tumors

Locally Advanced or Metastatic Solid Tumors

United States
CStone Pharmaceuticals

Completed

Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors

China
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

First-in-Human Study of MS201408-0005A as Single Agent and in Combinations

Metastatic or Locally Advanced Unresectable Solid Tumors

United States
Avistone Biotechnology Co., Ltd.

Not yet recruiting

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors

United States
Genexine, Inc.

Completed

Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors

Korea, Republic of
AstraZeneca

Completed

ARTEMIS DIANE T790M (An Amino Acid Substitution at Position 790 in EGFR, From a Threonine (T) to a Methionine (M)) Mutation at Hospital Laboratories in Comparison With Central Laboratory

Locally Advanced or Metastatic EGFR(+) NSCLC Patients

China
Merck Sharp & Dohme LLC
AstraZeneca

Completed

A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)

Locally Advanced or Metastatic Solid Tumors
AstraZeneca

Completed

A Retrospective, Non-interventional, Multicenter, Observational Chart Review Study to Explore the Clinical Benefits of Retreatment With TKI in the Real World. (SEQUENCE)

Locally Advanced or Metastatic EGFR Mutated NSCLC.

Taiwan
Txinno Bioscience Inc.

Recruiting

A Study of TXN10128 in Subjects With Solid Tumors

Locally Advanced (Unresectable) or Metastatic Solid Tumors

Korea, Republic of
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A First-in-human Study of IBI354 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Locally Advanced Unresectable or Metastatic Solid Tumors

Australia
FutureGen Biopharmaceutical (Beijing) Co., Ltd

Recruiting

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

Locally Advanced Unresectable or Metastatic Gastric Cancer | Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

China
Suzhou Transcenta Therapeutics Co., Ltd.

Terminated

Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Cancers | Metastatic Human Papillomavirus-Related Malignant Neoplasm

United States
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Multicentre,Study of IBI133 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumours

Locally Advanced Unresectable or Metastatic Solid Tumors

Australia
Jiangsu Simcere Pharmaceutical Co., Ltd.
Shanghai Xianxiang Medical Technology Co., Ltd.; Simcere Zaiming

Recruiting

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants With Advanced Solid Tumors

Locally Advanced Unresectable or Metastatic Solid Tumor

United States, China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Locally Advanced Unresectable or Metastatic Solid Tumors

Australia
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

Study of M1774 in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

Metastatic or Locally Advanced Unresectable Solid Tumors

United States, Canada, Spain
Hangzhou Sumgen Biotech Co., Ltd.

Recruiting

SG1906 for CLDN18.2-Positive Solid Tumors (CSG-1906-101)

Locally Advanced Unresectable or Metastatic Solid Tumors

China
Suzhou Junjing BioSciences Co., Ltd.
Sponsor GmbH

Not yet recruiting

A Study of WJ05129 in Advanced Malignant Solid Tumors

Locally Advanced or Metastatic Malignant Solid Tumors

China
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

Metastatic or Locally Advanced Unresectable Solid Tumors

United States, China, Spain, Japan, United Kingdom
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

First in Human Study of M1069 in Advanced Solid Tumors

Metastatic or Locally Advanced Unresectable Solid Tumors

United States, Canada

Clinical Trials on Locally Advanced or Metastatic Cancers

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations